Taysha Gene Therapies Inc
Taysha Gene Therapies Inc (TSHA) is a clinical-stage biotechnology company developing gene therapies for neurological and rare genetic disorders. With a market capitalisation of about $1.40 billion, Taysha focuses on delivering adeno-associated virus (AAV)‑based treatments designed to address root causes rather than symptoms. Investors should note the company is largely driven by clinical trial progress, regulatory milestones and potential partnerships or licensing deals. Like many gene‑therapy developers, Taysha faces binary outcome risk from trial results, significant research and development costs, and potential dilution if additional capital is required. That said, success in trials or a favourable regulatory path could meaningfully re‑rate the business. This summary is educational only and not personal financial advice; investors should consider their risk tolerance, investment horizon and seek independent advice before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Taysha Gene Therapies' stock, predicting it could rise to $10.57.
Financial Health
Taysha Gene Therapies is earning modest revenue and cash flow, indicating steady performance but potential challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring TSHA
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical programmes progress
Taysha’s value largely depends on trial outcomes and regulatory milestones, which can create opportunity but also binary downside risks.
Catalyst‑driven moves
Share price may react strongly to news such as trial readouts, partnerships or licensing deals, though performance can be volatile.
Manufacturing & access
Scaling gene‑therapy manufacturing and securing market access are crucial for long‑term value; these areas carry technical and commercial risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
